Skip to main content
Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.630
+0.070 (1.97%)
At close: Mar 9, 2026, 4:00 PM EDT
3.600
-0.030 (-0.83%)
After-hours: Mar 9, 2026, 4:00 PM EDT

Cellectis Revenue

Cellectis had revenue of $37.16M in the quarter ending September 30, 2025, with 105.89% growth. This brings the company's revenue in the last twelve months to $82.55M, up 129.04% year-over-year. In the year 2024, Cellectis had annual revenue of $49.22M with 435.37% growth.

Revenue (ttm)
$82.55M
Revenue Growth
+129.04%
P/S Ratio
3.31
Revenue / Employee
$371,851
Employees
222
Market Cap
273.34M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202449.22M40.02M435.37%
Dec 31, 20239.19M-16.53M-64.26%
Dec 31, 202225.72M-12.87M-33.35%
Dec 31, 202138.60M-20.97M-35.20%
Dec 31, 202059.56M36.57M159.09%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Coherus Oncology 277.73M
Fennec Pharmaceuticals 38.79M
OmniAb 18.67M
Prelude Therapeutics 10.50M
Ovid Therapeutics 6.61M
AC Immune 5.48M
Abeona Therapeutics 400.00K
Inhibikase Therapeutics 1.00
Revenue Rankings

CLLS News

More News